




Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration



## How to manage tenecteplase (Metalyse) shortage

The Therapeutic Goods Administration (TGA), in consultation with a range of stakeholders, is providing the following recommendations to help manage the tenecteplase (Metalyse) medicine shortage.

### What is in short supply?

Both strengths of the thrombolytic product tenecteplase (Metalyse), supplied by Boehringer Ingelheim, will be in shortage until the end of 2023.

### What does this mean?

Clinicians and health professionals must implement conservation methods to maintain continuity of supply in settings where there are no alternatives. To manage this shortage, use of tenecteplase must be reduced by 35% nationally.

### What to do

**From 1 October 2022, clinicians should:**

- ✓ Prioritise tenecteplase for pre-hospital thrombolysis (e.g. ambulance services).
- ✓ Prioritise tenecteplase for small rural and remote facilities/hospitals, including Aboriginal health services.
- ✓ Use alteplase in metropolitan and larger regional hospitals
- ✓ Find out which batch numbers of Metalyse have been given a 12 month extended shelf-life.
- ✓ Update Metalyse packaging to reflect the extended shelf-life to ensure stock is not accidentally disposed of.

### What not to do

- ✗ Do not stockpile Tenecteplase.
- ✗ Do not dispose of any out-of-date tenecteplase products. Set them aside pending a decision on expiry date extensions.

### For more information

- Supply and availability: 02 8875 8800
- About this statement: 02 6289 4646

Find out more on the TGA website [tga.gov.au](https://www.tga.gov.au)

